Bionovo (BNVIQ) 0.0049 $BNVIQ
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
Menopausal Hot Flashes - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmnp9b/menopausal_hot) has announced the addition of the "Menopausal Hot Flashes - Pipeline Review, H1 2013" report to their offering. 'Menopausal Hot Flashes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. Scope - A snapshot of the global therapeutic scenario for Menopausal Hot Flashes. - A review of the Menopausal Hot Flashes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
Menopausal Hot Flashes - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmnp9b/menopausal_hot) has announced the addition of the "Menopausal Hot Flashes - Pipeline Review, H1 2013" report to their offering. 'Menopausal Hot Flashes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. Scope - A snapshot of the global therapeutic scenario for Menopausal Hot Flashes. - A review of the Menopausal Hot Flashes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the
